PHILADELPHIA--(BUSINESS WIRE)--Aug. 29, 2006--Hemispherx Biopharma, Inc. (AMEX: HEB) announced the worldwide exclusive licensure of the international patent estate developed at Vanderbilt University for the in vivo use of the chemical compound DOGS, or dioctadecylamidoglycylspermine, for the efficient delivery of therapeutic DNA to the interior of cells.
